November 23rd 2020, 1:00pm
Patients with multiple sclerosis (MS) may not have an increased risk of contracting coronavirus disease 2019 (COVID-19), explained John Corboy, MD, of the University of Colorado Denver, School of Medicine.
November 20th 2020, 8:45pm
The shift to treat patients with pediatric-onset multiple sclerosis (POMS) who are treated earlier with a wider variety of medications has led to better outcomes, according to a recent study.
November 17th 2020, 12:45pm
Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, discusses how comorbidities affect treatment and options for patients with multiple sclerosis (MS).
November 13th 2020, 11:25pm
Which types of comorbidities have the greatest impact on direct and indirect costs of multiple sclerosis (MS) over time?
November 11th 2020, 9:45pm
Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute, explains how studies are trying to answer a debate about 2 approaches to treat multiple sclerosis (MS).
November 7th 2020, 12:45pm
Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, speaks about the overall prevalence of comorbidities in patients with multiple sclerosis (MS).
November 7th 2020, 1:00am
The study sought to determine if 2 specific types of adverse childhood experiences, abuse and neglect, are linked with multiple sclerosis (MS) and other immune-mediated inflammatory diseases.
October 31st 2020, 10:00am
The procedure might work best in patients who have had multiple sclerosis (MS) for less than 10 years, the report said.
October 30th 2020, 2:00pm
Quality of life for patients with multiple sclerosis (MS) could be better when they are off medication because they will not have adverse effects related to those medications, said John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine.
October 24th 2020, 9:30pm
Two abstracts presented at a recent multiple sclerosis meeting examined depression in pregnancy and pregnancy outcomes in ozanimod trials.
